Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials

Serge Jabbour*, Jochen Seufert, Andre Scheen, Clifford J. Bailey, Cathrina Karup, Anna M. Langkilde

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods: Data were pooled from 13 placebo-controlled trials of up to 24weeks' duration (dapagliflozin, n=2360; placebo, n=2295). Larger placebo-/comparator-controlled pools of 21 (≤208weeks; dapagliflozin, n=5936; control, n=3403) and 30 trials (≥12weeks; dapagliflozin, n=9195; control, n=4629) assessed the rare adverse events (AEs) of diabetic ketoacidosis (DKA) and lower limb amputation, respectively. Results: Over 24weeks, the overall incidence of AEs and serious AEs (SAEs) was similar for dapagliflozin and placebo: 60.0% vs 55.7% and 5.1% vs 5.4%, respectively. Rates of hypoglycaemia, volume depletion AEs, urinary tract infections (UTIs) and fractures were balanced between the groups. Genital infections were more frequent with dapagliflozin (5.5%) vs placebo (0.6%) and renal function AEs occurred in 3.2% vs 1.8% of patients (the most common renal AE was decreased creatinine clearance: 1.1% vs 0.7%). In the 21-study pool, 1 SAE of DKA and 3 AEs of ketonuria/metabolic acidosis occurred with dapagliflozin vs none with control; estimated combined incidence for these events was 0.03% (95% confidence interval 0.010-0.089). In the 30-study pool, lower limb amputation occurred in 8 (0.1%) and 7 (0.2%) patients receiving dapagliflozin and control, respectively. Conclusion: The overall incidence rates of AEs and SAEs were similar in the dapagliflozin and placebo/control groups, including the incidence of hypoglycaemia, volume depletion, fractures, UTIs, amputations and DKA. Genital infections were more frequent with dapagliflozin than placebo.

Original languageEnglish
Number of pages9
JournalDiabetes, Obesity and Metabolism
VolumeEarly view
Early online date26 Sep 2017
DOIs
Publication statusPublished - 26 Oct 2017

Bibliographical note

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Funding: AstraZeneca.

Keywords

  • Antidiabetic drug
  • Dapagliflozin
  • SGLT2 inhibitor
  • Type 2 diabetes

Fingerprint Dive into the research topics of 'Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials'. Together they form a unique fingerprint.

Cite this